Kymera Therapeutics, Inc.

NASDAQ:KYMR

49.03 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q3
Revenue 25.6510.28747.8854.72816.5139.46616.1399.55111.5149.62215.27520.33618.51918.70212.78514.5333.2883.4281.8330.95
Cost of Revenue 1.91.50.8650.90.90.90.8180.80.700000000000
Gross Profit 23.758.78747.023.82815.6138.56615.3218.75110.8149.62215.27520.33618.51918.70212.78514.5333.2883.4281.8330.95
Gross Profit Ratio 0.9260.8540.9820.810.9450.9050.9490.9160.93911111111111
Reseach & Development Expenses 57.30248.81952.9748.11745.76742.22743.13343.87741.29335.94437.5338.30635.2225.96220.39215.77813.81912.11611.08611.31
General & Administrative Expenses 17.37314.37414.22714.1214.12912.56511.63710.55611.03110.61111.7410.6678.0295.9095.1756.8383.6612.5592.531.501
Selling & Marketing Expenses 00000000000000000000
SG&A 17.37314.37414.22714.1214.12912.56511.63710.55611.03110.61111.7410.6678.0295.9095.1756.8383.6612.5592.531.501
Other Expenses 0-47.319000000000000000000
Operating Expenses 74.67561.69367.19762.23759.89654.79254.7754.43352.32446.55549.2748.97343.24931.87125.56722.61617.4814.67513.61612.811
Operating Income -50.925-52.906-19.312-57.509-43.383-45.326-38.631-44.882-40.81-36.933-33.995-28.637-24.73-13.169-12.782-8.083-14.192-11.247-11.783-11.861
Operating Income Ratio -1.985-5.143-0.403-12.163-2.627-4.788-2.394-4.699-3.544-3.838-2.226-1.408-1.335-0.704-1-0.556-4.316-3.281-6.428-12.485
Total Other Income Expenses Net 8.8634.3494.9444.6424.5844.3983.7661.880.5530.249-0.0510.0550.070.0940.0970.0970.2030.3150.270.441
Income Before Tax -42.062-48.557-14.368-52.867-38.799-40.928-34.865-43.002-40.257-36.684-33.901-28.582-24.66-13.075-12.685-7.986-13.989-10.932-11.513-11.42
Income Before Tax Ratio -1.64-4.72-0.3-11.182-2.35-4.324-2.16-4.502-3.496-3.813-2.219-1.405-1.332-0.699-0.992-0.55-4.255-3.189-6.281-12.021
Income Tax Expense 00.0394.996-0.8954.632-4.343-0.818-1.88-0.553-0.2490.0510.1250.0980.118-0.3730.1250.2280.3490.30.445
Net Income -42.062-48.557-14.368-52.867-38.799-36.585-34.047-41.122-39.704-36.435-33.901-28.582-24.66-13.075-12.685-7.986-13.989-10.932-11.513-11.42
Net Income Ratio -1.64-4.72-0.3-11.182-2.35-3.865-2.11-4.306-3.448-3.787-2.219-1.405-1.332-0.699-0.992-0.55-4.255-3.189-6.281-12.021
EPS -0.58-0.69-0.25-0.9-0.67-0.63-0.59-0.75-0.77-0.71-0.66-0.56-0.55-0.29-0.29-0.39-0.34-0.36-0.38-0.38
EPS Diluted -0.58-0.69-0.25-0.9-0.67-0.63-0.59-0.75-0.77-0.71-0.66-0.56-0.55-0.29-0.29-0.39-0.34-0.36-0.38-0.38
EBITDA -49.025-51.406-13.425-57.509-37.851-40.873-34.807-42.199-39.511-35.956-33.851-27.841-24.08-12.566-12.658-7.468-13.575-10.511-11.122-11.258
EBITDA Ratio -1.911-4.997-0.28-12.163-2.292-4.318-2.157-4.418-3.432-3.737-2.216-1.369-1.3-0.672-0.99-0.514-4.129-3.066-6.068-11.851